Lawsuit challenges anti-ageing claims
Telomerase Activation (TA) Sciences has been accused by former employee Brian Egan of conducting deceptive business practices, in promoting a herbal extract as having anti-ageing properties.
The lawsuit is focused on a pill called TA-65 which the company claims can slow or reverse degenerative effects caused by aging telomeres. Telomeres are nucleotide sequences that protect the ends of chromosomes when DNA replicates. Telomeres continue getting shorter and once they are gone, cells cannot reproduce because their DNA can no longer replicate. However, a telomerase enzyme exists that lengthens telomeres, and can slow or reverse degenerative diseases.
Egan, who took TA-65 was later diagnosed with prostate cancer and has accused TA Sciences of being responsible for his illness. However, TA Sciences argues that he must have had this cancer before starting the pill.
The creation of a legitimate telomere-lengthening compound would be an important development in treating people suffering from bone marrow failure or pulmonary fibrosis. However, the false promotion of such compound would be even more harmful to these patients.